170 related articles for article (PubMed ID: 11248162)
41. [HER-2/neu positive breast cancer: how to prescribe adjuvant trastuzumab (Herceptin)?].
Belkacémi Y; Gligorov J; Mauriac L; Azria D
Bull Cancer; 2006 Oct; 93(10):991-9. PubMed ID: 17074658
[TBL] [Abstract][Full Text] [Related]
42. 4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2/neu overexpressing advanced breast cancer: single institution prospective study.
Janku F; Pribylova O; Zimovjanova M; Pazdrova G; Safanda M; Zemanova M; Petruzelka L
Bull Cancer; 2004 Oct; 91(10):E279-83. PubMed ID: 15582895
[TBL] [Abstract][Full Text] [Related]
43. [The requirements to clinicopathology about targeted therapy for breast cancer].
Jiang ZF; Shen G
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):435-7. PubMed ID: 17845752
[No Abstract] [Full Text] [Related]
44. Treatment of trastuzumab-refractory, HER2-positive metastatic breast cancer.
Hurvitz S
Clin Adv Hematol Oncol; 2014 Apr; 12(4):260-2. PubMed ID: 25003356
[No Abstract] [Full Text] [Related]
45. From tumor size and HER2 status to systems oncology for very early breast cancer treatment.
Roukos DH; Ziogas D
Expert Rev Anticancer Ther; 2010 Feb; 10(2):123-8. PubMed ID: 20131987
[No Abstract] [Full Text] [Related]
46. Information for patients. HER2+ early breast cancer: understanding adjuvant treatment.
Helwick C
Oncology (Williston Park); 2009 Oct; 23(11 Suppl Nurse Ed):8a-8b. PubMed ID: 19856601
[No Abstract] [Full Text] [Related]
47. ASCO 2012: a good year for HER2 therapy.
Sledge GW
Clin Breast Cancer; 2012 Aug; 12(4):231. PubMed ID: 22858362
[No Abstract] [Full Text] [Related]
48. Adjuvant trastuzumab for HER2-positive breast cancer.
Spicer J; Harries M; Ellis P
Lancet; 2005 Aug 20-26; 366(9486):634. PubMed ID: 16112298
[No Abstract] [Full Text] [Related]
49. Overall survival in metastatic breast cancer: always our quest but not necessarily a primary endpoint.
Robert NJ
Breast Cancer Res Treat; 2010 Jul; 122(1):9-10. PubMed ID: 20495865
[No Abstract] [Full Text] [Related]
50. Re: Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects.
Magné N; Chargari C
Nat Clin Pract Oncol; 2008 Nov; 5(11):E1. PubMed ID: 18957967
[No Abstract] [Full Text] [Related]
51. Trastuzumab and breast cancer.
Rudlowski C; Rath W; Becker AJ; Wiestler OD; Buttner R
N Engl J Med; 2001 Sep; 345(13):997-8. PubMed ID: 11575298
[No Abstract] [Full Text] [Related]
52. Interstitial pneumonitis after treatment with bevacizumab and pegylated liposomal doxorubicin in a patient with metastatic breast cancer.
Huober J; Schoch O; Templeton A; Spirig C; Thürlimann B
Chemotherapy; 2010; 56(1):69-70. PubMed ID: 20145394
[No Abstract] [Full Text] [Related]
53. Cancer drug may cause heart failure.
Gottlieb S
BMJ; 2000 Jul; 321(7256):259. PubMed ID: 10915118
[No Abstract] [Full Text] [Related]
54. Chemotherapy-induced cardiotoxicity in women.
Dempsey KS
Crit Care Nurs Clin North Am; 2008 Sep; 20(3):343-50. PubMed ID: 18644518
[TBL] [Abstract][Full Text] [Related]
55. Dual HER2 inhibition and paclitaxel in metastatic breast cancer.
Brower V
Lancet Oncol; 2015 Feb; 16(2):e57. PubMed ID: 25577955
[No Abstract] [Full Text] [Related]
56. Reputation and precedent in the bevacizumab decision.
Carpenter D; Kesselheim AS; Joffe S
N Engl J Med; 2011 Jul; 365(2):e3. PubMed ID: 21707383
[No Abstract] [Full Text] [Related]
57. Adverse Mucocutaneous Reaction to Pertuzumab in a Patient with HER2-Positive Metastatic Breast Cancer.
Kowalczyk L; Singer CF; Staudigl C; Weber M; Farr A
Breast J; 2017 May; 23(3):352-353. PubMed ID: 27563723
[No Abstract] [Full Text] [Related]
58. [Therapy concept: herceptin in combination with arimidex].
von Minckwitz G
Onkologie; 2002 Dec; 25 Suppl 5():22 ; discussion 22-4. PubMed ID: 23573617
[No Abstract] [Full Text] [Related]
59. Steady progress against HER2-positive breast cancer.
Hayes DF
N Engl J Med; 2011 Oct; 365(14):1336-8. PubMed ID: 21991956
[No Abstract] [Full Text] [Related]
60. [Therapy concept: herceptin with anthracyclines].
Untch M
Onkologie; 2002 Dec; 25 Suppl 5():19-21; discussion 21. PubMed ID: 23573616
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
